RxDoctor Payments Data

Michelle Conger, DO

Family Medicine · Las Vegas, NVNPI 1730152703

Payments from drug & device makers

$1,434in general payments, 2019–2025

Across 75 payments — averaging $19.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$235
  • Biogen$211
  • AstraZeneca$162
  • Novo Nordisk$140
  • GSK$126
  • Boehringer Ingelheim$125
  • plus $435 from 12 others

What the payments were for

  • Food & beverage$1,434100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,434 in reported general payments places this provider in the 75th percentile of 902 family medicine providers in Nevada.

See all family medicine providers in Nevada

Medicare billing

Part B allowed, 2024
$24,549
Medicare patients
89
Services billed
243

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide236$299,009
EliquisApixaban106$109,565
JardianceEmpagliflozin86$103,813
OzempicSemaglutide70$84,276
Trelegy ElliptaFluticasone/Umeclidin/Vilanter81$57,307
FarxigaDapagliflozin Propanediol26$22,029
Stiolto RespimatTiotropium Br/Olodaterol Hcl22$10,631
XareltoRivaroxaban12$8,883
Rosuvastatin Calcium668$6,682
LinzessLinaclotide12$6,608
Lantus SolostarInsulin Glargine,hum.Rec.Anlog28$4,175
SymbicortBudesonide/Formoterol Fumarate15$4,114
Omeprazole220$3,927
Atorvastatin Calcium423$3,694
Losartan Potassium328$3,176

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Stiolto Respimat$125$114,443108 claims
PfizerEliquis$235$109,565106 claims
Novo NordiskOzempic$140$84,27670 claims
GSKTrelegy Ellipta$126$57,30781 claims
AstraZenecaFarxiga, Symbicort$162$26,14341 claims
Johnson & JohnsonXarelto$36$8,88312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 902 family medicine providers in Nevada.

Other family medicine in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →